Bioequivalence and Bioavailability Forum 03:07 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

bjkim97
Junior

Korea / Seoul,
2018-05-30 08:41

Posting: # 18828
Views: 599
 

 How to demonstrate the bioequivalence of sulodexide [Design Issues]

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,779 posts in 4,000 threads, 1,255 registered users;
online 16 (0 registered, 16 guests [including 14 identified bots]).

I have stopped reading Stephen King novels.
Now I just read C code instead.    Richard A. O'Keefe

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed